9H6U image
Deposition Date 2024-10-25
Release Date 2025-07-23
Last Version Date 2025-09-24
Entry Detail
PDB ID:
9H6U
Keywords:
Title:
SARS-CoV-2 S protein in complex with pT1679 Fab
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.27 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Spike glycoprotein,Fibritin
Gene (Uniprot):S, wac
Chain IDs:A
Chain Length:1273
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2, Tequatrovirus T4
Polymer Type:polypeptide(L)
Molecule:pT1679 Fab heavy chain
Chain IDs:B (auth: H)
Chain Length:259
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:pT1679 Fab light chain
Chain IDs:C (auth: L)
Chain Length:219
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation

Abstact

The emergence of pandemic coronaviruses remains a global health concern, highlighting the need for broadly neutralizing antibodies (bnAbs) that can target multiple sarbecoviruses. In this study, we isolated and characterized a novel antibody, pT1679, that demonstrates exceptional neutralization breadth. The antibody prevented infection with SARS-CoV-2 variants of concern, such as Omicron BA.1, and effectively neutralized pseudotyped viruses displaying S proteins from many SARS-CoV-2 variants and various bat and pangolin sarbecoviruses, including both SARS-CoV-like and SARS-CoV-2-like viruses. In addition, pT1679 reduced the viral load in the lung of infected Syrian hamsters and prevented the severe lung pathology typical for SARS-CoV-2 infections. The cryo-electron microscopy structure of pT1679 in complex with SARS-CoV-2 S revealed that the antibody employs a YYDRxxG motif to recognize a highly conserved epitope on the RBD. Through detailed structural analysis, mutagenesis studies, and binding assays, we identified RBD residue 384 as a critical determinant of antibody recognition. Structure-function analyses of several related bnAbs, such as COVA1-16, allowed for the classification of YYDRxxG antibodies into two distinct groups that differ in neutralization breadth. Our findings provide crucial insights into the molecular basis of broad Sarbecovirus neutralization and offer strategic guidance for selecting therapeutic antibodies in preparation for future Sarbecovirus outbreaks.IMPORTANCEThe threat of emerging coronaviruses demands therapeutic strategies capable of targeting both current and future circulating viruses. We report the discovery and characterization of pT1679, a broadly neutralizing antibody that demonstrates cross-reactivity against diverse sarbecoviruses, including SARS-CoV, SARS-CoV-2 variants, and related viruses from bats and pangolins. pT1679 targets a highly conserved epitope via a YYDRxxG motif in the paratope, with RBD residue 384 serving as a critical determinant of recognition. Our analysis allows for a classification of YYDRxxG antibodies, providing a framework for predicting antibody effectiveness against emerging sarbecoviruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures